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Abstract
New health technologies require development and evaluation ahead of being incorporated into the patient care 
pathway. In light of the recent publication by Lehoux et al who discuss the role of entrepreneurs, investors and 
regulators in providing value to new health technologies, we summarise the processes involved in making new 
health technologies available for use in the United Kingdom. 
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Health technologies can be used in health promotion, monitoring, prevention and treatment of disease. This includes medicines, medical devices, screening, 
etc. In the United Kingdom, ahead of a new medicine being 
licensed for use, it has to gain marketing authorisation for 
safety and efficacy ie, a licence from either the Medicines 
and Healthcare products Regulatory Agency (MHRA), the 
UK medicines and medical devices regulatory body, or the 
European Medicines Agency (EMA) after which the product 
can be used for the specified indications. Off-label use of 
medicines may occur when thought to be in the patient’s best 
interests either when an unlicensed drug is used or a licensed 
drug is used outside of its summary of product characteristics. 
A new medical device requires ‘CE’ (Conformité Européene) 
marking granted by an authorised European representative 
under the Medical Devices Directive, currently undergoing 
revision by the European Commission.1 This single validation 
for medical devices grants a European-wide licence. The 
regulatory authorities ensure a new health technology 
undergoes a thorough assessment not only as an intervention, 
but also for its economic value. Decision analytic modelling 
can provide an indication of the potential cost-effectiveness 
using current evidence-base, and help to inform further 
research priority.2 
The paper ‘Providing Value to New Health Technology: 
The Early Contribution of Entrepreneurs, Investors, and 
Regulatory Agencies’ discusses how entrepreneurs of 
new health technologies compromise to expedite sales 
and generate revenues, and how investors often support 
technologies that generate health gains by accident and not 
by design. Lehoux and colleagues also discuss how health 
technology assessments (HTAs) have been widely relied upon 
in decision making by policy-makers once the technology has 
been released into the market, and so prevents the ability to 
influence the development of that technology at an earlier 
stage.3
In the United Kingdom, HTAs are supported by the 
National Institute of Health Research (NIHR). The HTA 
programme is intended to fund work that would otherwise 
not be conducted, for example by industry through either 
commissioned or researcher-led work streams. This includes 
economic modelling, comparison of multiple different drugs, 
comparison of drugs with non-drug treatments, assessment 
of out-of-patent technologies, and testing effectiveness of 
technologies that are currently used but where the evidence is 
weak. The extent to which the HTA results are put into practice 
though vary significantly from study to study. Also, HTAs 
do not necessarily address the challenges or practicalities of 
implementation in the publicly funded UK National Health 
Service (NHS), an aspect funded through other streams 
such as Health Services and Delivery Research.4 All HTA 
work commissioned and funded by the NIHR is ultimately 
published in the international journal, Health Technology 
Assessment, which can help inform policy-makers.5
For the NHS, the National Institute for Health and Care 
Excellence (NICE) produce guidance regarding clinical and 
cost-effectiveness through assessing particular medicines 
and medical devices when there is geographic variation in 
the availability of a technology or confusion over its value 
across the United Kingdom, in particular in England.6 One 
of the many roles of NICE are Technology Appraisals. These 
are underpinned by Technology Appraisal Reviews (TARs), 
carried out by centres commissioned through the HTA 
programme ie, the research is conducted by the HTA followed 
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by recommendations made by NICE, which is unique to 
the United Kingdom. TARs are whereby NICE committees 
draw on experts in the field to base their recommendations 
for guidance on review of available clinical evidence and 
economic viability ie, how well the technology works in 
relation to the cost in the NHS helping standardise access to 
health technologies across the United Kingdom. These look 
at European and/or UK licensed drugs or approved medical 
devices. They can be single (single technology for a single 
indication) or multiple (more than one technology or one 
technology for more than one indication) which can take 
approximately 37 or 54 weeks, respectively. This is one of the 
key ways in which the HTA programme influences NICE 
guidance. There are four possible recommendation outcomes 
of a TAR process: recommended, optimised, only in research 
and not recommended. After the TAR recommendation is 
made by NICE, the NHS is legally obliged to fund and resource 
the recommendations within 3 months of its publication or 
specified date.7
We agree with Lehoux et al that policy makers should be 
involved at an early stage in order to review propositions of 
new health technologies and expedite innovation policies. 
NICE have a dedicated process for selecting technologies 
identified by the NIHR Horizon Scanning Centre at the 
University of Birmingham whereby they are informed of 
new drugs in development 20 months ahead of marketing 
authorisation and 15 months ahead of a new indication.8 
They also welcome suggestions of new medicinal products 
(which are to receive a marketing authorisation) through UK 
PharmaScan or from healthcare professionals, researchers and 
patients. Their work is based on national and local planning 
as well as development of commissioning policies for new 
medicines ie, to help the timetabling of HTAs by NICE, and 
support local budget planning and formulary development.9 
If a technology receives formal referral by the Department 
of Health, NICE can then consider a patient access scheme 
(financial or outcomes based) and/or flexible pricing 
proposals (schemes proposed by a company to help facilitate 
patient access to a technology) in order to be at the forefront 
of high-end patient care delivery. In the United Kingdom, 
last year the Department of Health published the Accelerated 
Access Review, which aims to get a medicine from ‘bench-to-
bedside’ for use on England’s NHS quicker, through reducing 
the process by up to four years.10 This would be highly 
regarded by both entrepreneurs and innovators alike.
There is a lot of uncertainty facing the healthcare system 
ahead of the UK’s departure from the European Union (EU) 
where at the time of writing this commentary negotiations are 
being initiated for the terms and conditions and the financial 
implications of “Brexit.” In the absence of a UK-EU mutual 
agreement, there will be a large shortfall in funding for UK 
Research and Innovation once it is no longer eligible for 
European Research Council funding. 
Health technologies that involve European pathways such 
as granting of marketing authorisations through the EMA, 
the Medical Device Directive and the future of medical 
devices’ ‘CE’ marking will need to be addressed as a matter 
of urgency to avoid any delays in access to new technologies. 
It is important for both the UK medical technology industry 
and NHS to work together to retain influence over future 
European regulation as one of the largest healthcare providers 
in the world.11 They will also need to be able to continue to 
negotiate the development of new technologies and prevent 
any restriction of the ability of UK manufacturers to export 
medical devices into the large European medical technology 
market.
Regulatory agencies must maintain their attention towards 
safety and efficacy, but must be rationalised if they are to 
afford more efficiency in the face of a rapidly evolving medical 
technology innovation sector and the flat/reduced NHS 
hospital budgets available to fund these innovations. This 
also relies on the development and maintenance of a resilient 
and adaptable infrastructure so that the healthcare system 
is not overwhelmed by new technologies and information 
to monitor their performance is collected accurately and 
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